Mission, vision and strategy

Biotest Next Level

Biotest will more than double the production capacity of the Biotest Group with the "Biotest Next Level" investment programme. This programme includes the construction of a basic plasma fractionation facility with 1.4 million litre capacity, and bulk production plants for Albumin, new Fibrinogen and Trimodulin (IgM Concentrate)  product lines, and next-generation polyvalent immunoglobulins.

The new production building, which is supplied by its own combined heat and power plant energy centre, was built according to the latest regulations of the German energy-saving regulations (EnEV 2015) and the German renewable energy act.

 

Combined heat and power plant and production building Biotest Next Level

Biotest Next Level

Biotest Next Level

Production facility

Production facility

Buffer storage for immunoglobulins

Buffer storage for immunoglobulins

Media supply flor

Media supply flor

Infrastructure measures as a prerequisite for expansion

The new construction of the plasma receiving area and the virological laboratories created the preconditions for the larger production capacity of the new plant.
 

Plasma receiving area and virological laboratories

Plasma receiving area and virological laboratories

 

The construction of the multi-storey car park freed up space for the construction of the Biotest Next Level production facility on the former employee car park.
 

Employee car park with 700 parking spaces. 19 electric charging stations for free charging are installed there and will be further expanded as demand requires.

Employee car park with 700 parking spaces. 19 electric charging stations for free charging are installed there and will be further expanded as demand requires.

 

Strategic focus of the Biotest Next Level project

  • Increase of capacity

  • Globalisation of products

  • More products from one litre of plasma

  • Improved yield

  • Special plasma products (high medical need)


In total, Biotest is investing  600 million euros at the Dreieich site and creating 300 new jobs. With this capital expenditure, Biotest not only underlines its strategy of investing in growth and the development of new products, but also its commitment to the Rhine-Main area.